Investor Overview

Latest News Releases

2023 Annual Report

Neurocrine Biosciences has four commercial, FDA-approved treatments in the United States and a robust pipeline.

Annual Reports

Stock Quote

(Common Stock)

Change
Volume
52 Week High
52 Week Low

10/17/24 10:52 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed

Latest Filings

Filing date	Form	Description	Filing Group	View
11/01/24	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000914475-24-000214.pdf 0000914475-24-000214.rtf 0000914475-24-000214.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
11/01/24	4	Statement of changes in beneficial ownership of securities	3,4,5	View HTML 0000914475-24-000216.pdf 0000914475-24-000216.rtf 0000914475-24-000216.xls
10/30/24	8-K	Report of unscheduled material events or corporate event	Current Reports	View HTML 0000914475-24-000210.pdf 0000914475-24-000210.rtf 0000914475-24-000210.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.

Corporate Sustainability

Our ESG programs are aligned to our purpose, which we fulfill
through effective management of critical environmental, social, and
governance principles that are fundamental to our business.

2022 ESG Report